Zacks Research Issues Negative Outlook for VRTX Earnings

Zacks Research has lowered its Q2 2027 earnings per share estimates for Vertex Pharmaceuticals from $4.60 to $4.45. Despite this, Vertex reported strong Q3 earnings of $4.80 per share, surpassing the consensus estimate of $4.58. The company's revenue for the quarter was $3.08 billion, up 11% year-over-year. Various analysts have adjusted their price targets for Vertex, with ratings ranging from 'buy' to 'hold'. Vertex's stock is currently trading at $429.82, with a market cap of $109.05 billion.

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Investment analysts at Zacks Research decreased their Q2 2027 earnings per share estimates for shares of Vertex Pharmaceuticals in a research report issued on Monday, November 24th. Zacks Research analyst Team now forecasts that the pharmaceutical company will post earnings per share of $4.45 for the quarter, down from their previous forecast of $4.60. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter in the prior year, the company earned $4.38 earnings per share. The company's quarterly revenue was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Get Vertex Pharmaceuticals alerts:

Best Biotech Stocks to Buy in 2025

Other analysts have also issued research reports about the stock. HC Wainwright decreased their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating for the company in a research note on Tuesday, August 5th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Vertex Pharmaceuticals in a report on Wednesday, October 8th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an "outperform" rating in a report on Tuesday, August 5th. Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, August 5th. Finally, Cantor Fitzgerald dropped their target price on Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating on the stock in a report on Tuesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eleven have assigned a Hold rating to the company. Based on data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $491.95.

Check Out Our Latest Research Report on VRTX

Vertex Pharmaceuticals Stock Up 1.4%

MaxCyte: Building the Future of Cell and Gene Therapy Innovation

Shares of NASDAQ:VRTX opened at $429.82 on Wednesday. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.68. The stock's 50 day moving average is $412.78 and its 200-day moving average is $424.99. The firm has a market capitalization of $109.05 billion, a price-to-earnings ratio of 30.72 and a beta of 0.36.

Insider Activity

In related news, Chairman Jeffrey M. Leiden sold 53,604 shares of the stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $440.72, for a total transaction of $23,624,354.88. Following the completion of the sale, the chairman directly owned 24,026 shares of the company's stock, valued at approximately $10,588,738.72. This trade represents a 69.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Activest Wealth Management purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth about $25,000. Chesapeake Asset Management LLC boosted its stake in Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company's stock valued at $25,000 after acquiring an additional 33 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in Vertex Pharmaceuticals by 450.0% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 45 shares during the last quarter. Access Investment Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $27,000. Finally, Colonial Trust Co SC grew its position in shares of Vertex Pharmaceuticals by 118.8% during the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock valued at $27,000 after acquiring an additional 38 shares during the period. Institutional investors own 90.96% of the company's stock.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Five stocks we like better than Vertex Pharmaceuticals
What Are Dividend Challengers?
History Says These are 3 Stocks to Buy for December
How to Know if a Stock Pays Dividends and When They Are Paid Out
Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
EV Stocks and How to Profit from Them
From Science Project to Solvent: WeRide’s 761% Revenue Surge

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?

Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here